Researchmoz added Most up-to-date research on "Global Combined Hormonal Contraceptives (CHC) Market: Trends and Opportunities (2014-19)" to its huge collection of research reports.
The report titled “Global Combined Hormonal Contraceptive (CHC) Market: Trends and Opportunities (2014-2019)” provides an in-depth analysis of the global CHC market with detailed analysis of market sizing and growth, market share and economic impact of the industry. The report also assesses key opportunities in the market and outlines the factors that are and will be driving growth of the industry. Growth of the overall CHC industry has also been forecasted for the period 2014-19, taking into consideration the previous growth patterns, the growth drivers and the current and future trends. An insight into strategic issues affecting key brands on the market is provided followed by an analysis of the leading companies in the hormonal contraceptives market. The report also analyzes the key CHC products in pipeline.Further, key players of the industry like Agile Therapeutics; Bayer Healthcare; Teva Pharmaceuticals and Actavis PLC; are analyzed in the report.
To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=242913
- Country Coverage
- United states
- United Kingdom
- India
- China
- Japan
- Company Coverage
- Agile Therapeutics Inc.
- Actavis Plc.
- Bayer Healthcare
- Teva Pharmaceuticals
Executive Summary
Combined Hormonal Contraceptives (CHC) is widely being used as an effective and reversible birth control method. Mainly used for preventing pregnancies but sometimes also used for treating acne vulgaris, endometriosis, polycystic ovarian syndrome and irregular menstrual flow, CHC works by preventing ovulation i.e. release of egg from ovaries. The hormones are provided in the combined pill, patch or ring.
Most popular Combined Hormonal Contraceptives products are Nuvaring and Ortho Evra. CHC products are broadly used throughout the world by women in the age-group of 15 to 49 years. With increasing health consciousness and awareness, adoption of CHC products or birth control methods is increasing in lesser privileged economic segments too. The growth of CHC market is driven by urbanization and increasing user awareness, rise in menstruating population globally and initiatives taken by governments to encourage the use of contraception. Major trends prevailing in the market are the increasing number of mergers and acquisitions in this business space and demand for reversible method of contraception with fewer side effects.
Make an Enquiry of this report @ http://www.researchmoz.us/enquiry.php?type=E&repid=242913
The report titled “Global Combined Hormonal Contraceptive (CHC) Market: Trends and Opportunities (2014-2019)” provides an in-depth analysis of the global CHC market with detailed analysis of market sizing and growth, market share and economic impact of the industry. The report also assesses key opportunities in the market and outlines the factors that are and will be driving growth of the industry. Growth of the overall CHC industry has also been forecasted for the period 2014-19, taking into consideration the previous growth patterns, the growth drivers and the current and future trends. An insight into strategic issues affecting key brands on the market is provided followed by an analysis of the leading companies in the hormonal contraceptives market. The report also analyzes the key CHC products in pipeline.Further, key players of the industry like Agile Therapeutics; Bayer Healthcare; Teva Pharmaceuticals and Actavis PLC; are analyzed in the report.
To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=242913
- Country Coverage
- United states
- United Kingdom
- India
- China
- Japan
- Company Coverage
- Agile Therapeutics Inc.
- Actavis Plc.
- Bayer Healthcare
- Teva Pharmaceuticals
Executive Summary
Combined Hormonal Contraceptives (CHC) is widely being used as an effective and reversible birth control method. Mainly used for preventing pregnancies but sometimes also used for treating acne vulgaris, endometriosis, polycystic ovarian syndrome and irregular menstrual flow, CHC works by preventing ovulation i.e. release of egg from ovaries. The hormones are provided in the combined pill, patch or ring.
Most popular Combined Hormonal Contraceptives products are Nuvaring and Ortho Evra. CHC products are broadly used throughout the world by women in the age-group of 15 to 49 years. With increasing health consciousness and awareness, adoption of CHC products or birth control methods is increasing in lesser privileged economic segments too. The growth of CHC market is driven by urbanization and increasing user awareness, rise in menstruating population globally and initiatives taken by governments to encourage the use of contraception. Major trends prevailing in the market are the increasing number of mergers and acquisitions in this business space and demand for reversible method of contraception with fewer side effects.
Make an Enquiry of this report @ http://www.researchmoz.us/enquiry.php?type=E&repid=242913
No comments:
Post a Comment